Search

Your search keyword '"Uterine Cervical Neoplasms therapy"' showing total 339 results

Search Constraints

Start Over You searched for: Descriptor "Uterine Cervical Neoplasms therapy" Remove constraint Descriptor: "Uterine Cervical Neoplasms therapy" Topic neoplasm recurrence, local Remove constraint Topic: neoplasm recurrence, local
339 results on '"Uterine Cervical Neoplasms therapy"'

Search Results

1. Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.

2. Long-term analysis of hematological parameters as predictors of recurrence patterns and treatment outcomes in cervical cancer patients undergoing definitive chemoradiotherapy.

3. Advances in systemic treatment for recurrent metastatic cervical cancer.

4. The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer.

5. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I).

6. Investigation of the clinical implications of anterior cervical invasion in locally advanced cervical squamous cell carcinoma.

7. Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers.

8. Integrating cat boost algorithm with triangulating feature importance to predict survival outcome in recurrent cervical cancer.

9. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.

10. MRI radiomics nomogram integrating postoperative adjuvant treatments in recurrence risk prediction for patients with early-stage cervical cancer.

11. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.

13. Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.

14. Vaginal microbial profile of cervical cancer patients receiving chemoradiotherapy: the potential involvement of Lactobacillus iners in recurrence.

15. Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.

16. Chemoradiotherapy-induced ACKR2 + tumor cells drive CD8 + T cell senescence and cervical cancer recurrence.

17. MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.

18. Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.

19. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.

20. The role of high-risk HPV testing in cervical cancer surveillance.

21. Post-recurrence survival in patients with cervical cancer.

22. Predicting the risk of the distant recurrence of cervical cancer after concurrent chemoradiation: A validation study of the Korean Gynecologic Oncologic Group (KGOG)-1024 model.

23. The significance of post-radiotherapy parametrial involvement and the necessity of parametrial resection in locally-recurrent or persistent cervical cancer developed after radiotherapy.

24. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.

25. Serum conversion pattern of SCC-Ag levels between pre- and post-chemoradiotherapy predicts recurrence and metastasis in cervical cancer: a multi-institutional analysis.

26. Late Radiation-Related Toxicities in Patients Treated for Early-Stage Cervical Carcinoma by Surgery and Adjuvant Radiotherapy: A Retrospective Imaging Study.

27. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.

28. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.

29. Conservative treatment of microinvasive squamous cell carcinoma of the cervix stage IA1: Defining conization height to an optimal oncological outcome.

30. Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.

31. Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2).

32. The predictive recurrence value of MTV-s as an 18F-FDG PET/CT index in patients with IIB-IVA cervical cancer.

33. The impact of Aurora kinase A genetic polymorphisms on cervical cancer progression and clinicopathologic characteristics.

34. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.

35. Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.

36. The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes.

37. Tumor budding in cervical cancer as a prognostic factor and its possible role as an additional intermediate-risk factor.

38. Advances in immunotherapy for cervical cancer.

39. Oncological management of pregnancy-associated cancers: analysis from the French CALG (Cancer Associé à La Grossesse) network.

40. Tailored radical hysterectomy for locally advanced cervical cancer.

41. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.

42. Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.

43. Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer.

44. Definitive chemoradiotherapy for cervical cancer: A 11-year population-based study.

45. The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population.

46. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.

47. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

48. MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study.

49. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

50. Indicators of survival and prognostic factors in women treated for cervical cancer at a tertiary care center in Saudi Arabia.

Catalog

Books, media, physical & digital resources